Our most advanced project’s lead optimization results published

Novel 8-hydroxyquinoline pharmacophore scaffold was synthetized by Avidin’s Medicinal Pharmacolgy department which has been shown to possess a range of activities as metal chelation, enzyme inhibition, cytotoxicity and cytoprotection. Based on our previous findings we set out to optimize the scaffold for cytoprotective activity for its potential application in central nervous system related diseases. A 48-membered Betti-library was constructed by the utilization …

Avidin organized the fifth TAT-CF general assembly held in Budapest.

The famous Géllert Hotel was the venue selected for meeting. Thursday 14th was dedicated to a workshop session where all the partners presented the most recent progress in their respective work packages. Exciting results from TAT-CF selected hits raised the expectations toward a successful outcome of the project. A total of 10 presentations from the eight TAT-CF partners reviewed all …

Lewis Acid-Catalyzed Diastereoselective Synthesis of Multisubstituted N-Acylaziridine-2-carboxamides from 2H-Azirines via Joullié–Ugi Three-Component Reaction

Lewis Acid-Catalyzed Diastereoselective Synthesis of Multisubstituted N-Acylaziridine-2-carboxamides from 2H-Azirines via Joullié–Ugi Three-Component Reaction (doi: 10.1021/acs.joc.7b03189) 3-9-2018 Avidin’s Medicinal Chemistry Department developed and established an innovative protocol for a ZnCl2-catalyzed diastereoselective Joullié-Ugi three-component reaction from 2 H-azirines, isocyanides, and carboxylic acids. The protocol allows the preparation of highly and diversely functionalized N-acylaziridine-2-carboxamide derivatives in up to 82% isolated yields. Additionally, the applicability …

Our single cell protection buffer, the SingleCellProtectTM

Our single cell protection buffer, the SingleCellProtectTM  was used in a recently published Nature Communication paper (doi:10.1038/s41467-017-02628-4) 3-4-2018 Previously we showed that single cells collected for genomic analysis without our protection buffer resulted in more variations and less RNA both in RNASeq and quantitative real-time PCR methods. Our specially formulated solution the SingleCellProtectTM ensures excellent quality RNA for single cell …

Avidin joined to fourth cystic fibrosis consortium (H2020 TAT-CF) progress meeting in Mallorca (Spain)

Day one was dedicated to the 3rd TAT-CF workshop in which researchers from all partners presented their work within the H2020 project (Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters No 667079). The second day, principal investigators discussed key issues during the Steering Committee meeting. The project has entered into its last year …

Recent Press release announced Hungarian companies can make a breakthrough in combating Alzheimer’s disease

The fruitful collaboration of AVIDIN Ltd. and SONEAS Research Ltd. working in the field of drug development has produced outstanding results from professional and also business point of view. AVIDIN Ltd. has dedicated to pharmaceutical research of Alzheimer’s disease from 2009. During the company’s chemical and molecular-level biological development, a novel drug candidate Q134R-K was discovered which has been patented …

Avidin’s chemistry R&D unit divided into new Divisions

Avidin’s chemistry R&D unit responsible for chemical synthesis and development was divided into two Divisions: Medicinal Chemistry Department lead by Iván Kanizsai, PhD and Organic Chemistry Department, where Árpád Balázs, PhD was appointed as the leader. Medicinal Chemistry Department is responsible for hit discovery and lead optimization supporting different drug discovery programs. Organic Chemistry Department is responsible for chemical development, …

Avidin participated in cystic fibrosis consortium meeting

Horizon 2020 Consortium meeting was held on Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembrane anion transporters in Copenhagen, Denmark July 4-6 2017 . The meeting of the Steering Committee has included the review of the project progress, milestones and planning of actions for the next six months together with the second TAT-CF Workshop. ...

Avidin awarded with innovative, European Union grant to promote flexible work schedule

Avidin Ltd. has been funded to launch and promote the “Introducing the flexible work schedule” as part of the Economic Development and Innovation Operational Program. Funding amount: 11 789 990 Ft Funding percentage: 100% Expected end of the project: 30.06.2018. Identification number of the project: GINOP-5.3.2-16-2016-00083 Under this project the flexible work schedule is designed to better harmonize the work ...

Poster in the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Avidin is presenting a poster in collaboration with Sanders-Brown Center on Aging, University of Kentucky at the AD/PDTM 2017 meeting, the 13th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders on Thursday, March 30, 2017. Poster: Presentation number: 138 Authors: Christopher M. Norris, Susan D. Kraner, Melanie M. Pleiss, Pradoldej Sompol, Irina A. Artiushin, Orsolya Huzian, Laszlo …